Yes Skiier. I also noticed that. I didn’t understand why they remain unblinded. That doesn’t make sense but I believe there are lots of lies happening here. I also believe they are not selling Bert outright. They are simply doing a partnership for BP indication. So they don’t need to open up that trial to anyone. I also like your idea as well which would be to put a forward looking clause in there allowing the bidders to top up their bids once UC results are released. That also makes sense. I have always remained focused on BP results. Yes it’s the smaller indication but the disease is horrific and debilitating. The fact alone that it reduced steroid use down to almost nothing means that this could be a all in one treatment. It’s simply amazing. But UC is far larger indication. I believe that there’s a lot more things that must be done in that trial and when comparing to precedent drugs. I’m assuming they do that. But we are literally the only drug for BP therefore creating our own precedence. Which to me is bombastic. From my research, I’ve learned that they are struggling with getting stand alone drugs to market, so now pharms have been mixing drugs from ancient days and trying see if they can use old drugs for new indications. It’s quite remarkable. It does show you that there is a lot out there but no one wants to share. But Our Bert agent is amazing. It needs basically no help to treat BP. I’m excited if we are allowed ownership here.
News 
Market Data 
Discover 
AI
